anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
This is an open-label 96-week extension study of open-label simufilam 100 mg b.i.d. for subjects who completed the Phase 2 study, PTI-125-04. All subjects will provide consent to enroll into this study. Simufilam will be administered as coated oral tablets. The last study visit, Month 24, from the PTI-125-04 study will be used for the Study Day 1 visit assessments in this extension study. Clinic visits will occur every 12 weeks ±10 days. A complete physical examination will be performed at Study Day 1, Week 48 and Week 96. Subjects will return to the clinic every 12 weeks for safety assessments of vital signs, AE monitoring, C-SSRS, and drug dispensation and accountability. Blood draws for clinical laboratory testing, urine collection for urinalysis, and ECGs will be performed at Study Day 1 and Weeks 24, 48, 72, and 96. Safety will be evaluated by adverse event monitoring, vital signs, clinical labs, and the Columbia Suicide Severity Rating Scale (C-SSRS).
A kind of hydrochloric piperphentonamine freeze-dried powder injection and their preparation methods. The injection is formed by freezing and drying with one portion of hydrochloric piperphentonam- ine, 2.5-30 portions of excipients and 400-600 portions of water for injection with pH=1.5-5.5. Excipient can be mannitol, dextran, lactosemilk sugar, saccharose, polyethylene glycol, poloxamer, Gly etc. It is preferred that the injection comprises one portion of hydrochloric piperphentonamine, 10 portions of excipients and 500 portions of water for injection with pH=2.0-3.0. The preparation method for the injection includes adding said hydrochloric piperphentonamine and excipient(s) into water, heating at 40-90 ?, being treated by ultrasonic wave, degerming, subpackage split charging,prefreezing,multistage' s drying, packaging to obtain the production. Controlled glass bottle is used and the brown is preferred. The appearance, colour & luster and solubility of the injection are excellent. It has good stability and long retention time. The uses of the injection in the preparation of medicament for heart failure and/or myocardial preservation.
Two FDG-PET/CT scans prior to 1st cycle of chemotherapy, plus 2 optional volumetric CT scans. One FDG-PET/CT after 1st cycle of chemotherapy, plus 1 optional volumetric CT scan.
INTRODUCTION: In the Transversus Abdominis Release (TAR) procedure, ideally, the posterior sheath is completely reapproximated to establish an interface isolating the polypropylene mesh from visceral contents. When primary closure of the posterior sheath is unachievable, Vicryl mesh is commonly used to supplement the posterior sheath closure and an uncoated polypropylene mesh is placed superficial to the Vicryl mesh. The long-term implications of utilizing Vicryl mesh as an antiadhesive barrier are poorly understood. In this study, we aimed to assess our outcomes when utilizing Vicryl mesh to supplement the posterior sheath defects when placed underneath polypropylene mesh in patients undergoing posterior component separation.
METHODS: Adult patients who underwent VHR with concurrent TAR procedure with a permanent synthetic mesh and posterior sheath supplementation with Vicryl mesh in the Cleveland Clinic Center for Abdominal Core Health between January 2014 and December 2022 were queried retrospectively from a prospectively collected database in the Abdominal Core Health Quality Collaborative. We evaluated 30-day wound morbidity, perioperative complications, long-term mesh-related complications, and pragmatic hernia recurrence.
RESULTS: 53 patients who underwent TAR procedure with posterior sheath supplementation using Vicryl mesh and had a minimum 12-month follow-up were identified. Of the 53 patients, 94.3% presented with recurrent hernias, 73.6% had a midline hernia, 7.5% had a flank hernia, and 18.9% had concurrent parastomal hernia. The mean hernia width was 24.9 cm (± 8.8 cm). No Vicryl mesh-related operative complications were identified in our study, with no instances of mesh erosion, fistulas, or interventions for small bowel obstruction. Skin necrosis requiring reoperations was observed in three patients (5.7%), leading to permanent mesh excision in two cases (3.8%) without intraabdominal visceral involvement. Throughout the 12-month follow-up, 23 incidences (43.4%) of surgical site occurrences (SSOs) and surgical site occurrences requiring procedural intervention (SSOPI) were documented.
CONCLUSIONS: Our findings suggest that posterior sheath supplementation with Vicryl mesh is a feasible approach to achieve posterior sheath closure in challenging abdominal wall reconstruction cases. Given the absence of notable mesh-related complications and a similar hernia recurrence rate to cases without posterior sheath supplementation, Vicryl mesh can be used to safely achieve posterior sheath closure in complex reconstructions with insufficient native tissue.
The present invention is directed to an autocrine growth factor isolated from a human germ cell tumor line. In particular, it relates to the production, purification and uses of stem cell proliferation factor (SCPF). The protein of the invention exists in two foams, a soluble form and a membrane bound form which is detectable on the surface of a small percentage of human. bane mar-row cells and stimulates the proliferation of these cells. Therefore, SCPF may have a wide range of applications including but not limited to augmenting the growth of hematopoietic stem cells. Further, removal of the protein by an antibody may be useful in controlling tumor cell growth.
BACKGROUND: Chronic nausea and vomiting syndromes (CNVS), gastroparesis and functional dyspepsia (FD) are complex disorders. Body Surface Gastric Mapping (BSGM), a new test of gastric function, using Gastric Alimetry® (Alimetry, New Zealand) may be useful for de-escalating healthcare utilisation. This study aimed to define healthcare costs and estimate health economic impacts of implementing this test in patients with chronic gastroduodenal symptoms.
METHODS: Consecutive patients at a tertiary referral centre evaluated with Gastric Alimetry were included. Frequency and cost data relating to medical investigations, hospital and outpatient presentations were evaluated. Costs of healthcare utilisation were calculated, and the potential cost savings of implementing Gastric Alimetry within a diagnostic decision-tree model were estimated.
RESULTS: Overall, 31 consecutive patients (mean age 36.1 years; 83.9% female; predominant symptoms: nausea [83.9%], pain [61.3%], vomiting [67.7%] and bloating [35.5%]) completed Gastric Alimetry testing. Repeat gastroscopy and abdominal CT rates were 29% (8/28) and 85% (11/13), respectively. Gastric Alimetry testing identified spectral abnormalities in 45.2% of patients, and symptom profiling classified a further 29.1% of patients. Median annualised cost difference after test introduction was NZ$-12,032. Estimated reductions in investigation-related costs when incorporating Gastric Alimetry into the diagnostic workflow model were approximately NZ$1,300 per patient.
CONCLUSIONS: Healthcare utilisation and confirmatory testing rates remain high in nausea and vomiting syndromes. This study presents real-world data, together with a decision-tree analysis, showing Gastric Alimetry can streamline clinical care pathways, resulting in reduced healthcare utilisation and cost.
FIELD: medicine, immunology, pharmacy. SUBSTANCE: invention relates to medicinal agents and represents the new pharmaceutical composition comprising anti-Fas-antibody that can be used as an agent for prophylaxis and/or treatment of autoimmune disease or rheumatic arthritis. Invention represents a pharmaceutical composition comprising as active components antibody raised against human Fas that elicits apoptosis-inducing activity and compound with activity of folate antagonist or activity inhibiting dihydrofolate reductase. Amount of anti-Fas-antibody that is necessary to use for prophylaxis and/or treatment of autoimmune disease or rheumatic arthritis can be reduced and, therefore, to diminish probability that patient will acquire the tolerance to anti-Fas-antibody as result of producing antibodies against anti-Fas-antibody in the patient body. Invention provides expanding assortment of prolonged agents used for prophylaxis and/or treatment of autoimmune diseases. EFFECT: enhanced effectiveness of composition, valuable medicinal properties. 35 cl, 3 dwg, 2 ex
Swallow CYMBALTA whole. Do not chew or crush. Do not open the capsule and sprinkle its contents on food or mix with liquids. All of these might affect the enteric coating. CYMBALTA can be given without regard to meals. If a dose of CYMBALTA is missed, take the missed dose as soon as it is remembered. If it is almost time for the next dose, skip the missed dose and take the next dose at the regular time. Do not take two doses of CYMBALTA at the same time.
Participants will apply DBV712 250 mcg, epicutaneous system (or patch), daily for a period of 2 additional years if they were randomized DBV712 250 mcg or for 3 years if they were randomized placebo. After 12 months of open-label treatment with DBV712 250 mcg, (i.e., at the end of Month 24), participants will undergo a peanut DBPCFC according to the following schedule: 3, 10, 30, 100, 300, 600, 1000, and 2000 mg (4043 mg cumulative dose). Participants who were randomized to placebo will also undergo an additional peanut DBPCFC after 24 months of open-label treatment with DBV712 250 mcg, (i.e., at the end of Month 36).
Compositions comprising carboxypolysaccharides (CPS) including carboxymethyl cellulose (CMC) and polyethylene glycols (PEGs) are provided where the PEG is a PEG-epoxide covalently linked to the CPS via an addition reaction. In certain embodiments, the PEG attaches to only one CPS, forming a decorated CPS. In other embodiments, bi-functional PEG molecules are attached to adjacent CPSs, thereby forming a covalently cross-linked composition. In certain of these embodiments, a PEG is linked to the CPS by way of an ether linkage, and in other embodiments, a PEG is linked to the CPS by way of an ester linkage, and in still further embodiments, PEG molecule(s) can be attached to CPS molecule(s) by way of both ether and ester linkages. Additional embodiments include PEG/CMC compositions where the PEG is a multi-branch PEG and/or a multi-arm PEG. PEG/CMC compositions can be made with desired viscoelastic properties, and such compositions can be used as space-filling materials, load-bearing materials, anti-adhesion compositions, for drug delivery vehicles or for lubrication of tissues and medical instruments.
The pharmacokinetics of nitric oxide has been studied in adults.

Absorption and Distribution

Nitric oxide is absorbed systemically after inhalation. Most of it traverses the pulmonary capillary bed where it combines with hemoglobin that is 60% to 100% oxygen-saturated. At this level of oxygen saturation, nitric oxide combines predominantly with oxyhemoglobin to produce methemoglobin and nitrate. At low oxygen saturation, nitric oxide can combine with deoxyhemoglobin to transiently form nitrosylhemoglobin, which is converted to nitrogen oxides and methemoglobin upon exposure to oxygen. Within the pulmonary system, nitric oxide can combine with oxygen and water to produce nitrogen dioxide and nitrite, respectively, which interact with oxyhemoglobin to produce methemoglobin and nitrate. Thus, the end products of nitric oxide that enter the systemic circulation are predominantly methemoglobin and nitrate.

Metabolism

Methemoglobin disposition has been investigated as a function of time and nitric oxide exposure concentration in neonates with respiratory failure. The methemoglobin (MetHb) concentration-time profiles during the first 12 hours of exposure to 0, 5, 20, and 80 ppm nitric oxide are shown in Figure 1.

Methemoglobin concentrations increased during the first 8 hours of nitric oxide exposure. The mean methemoglobin level remained below 1% in the placebo group and in the 5 ppm and 20 ppm nitric oxide gas groups, but reached approximately 5% in the 80 ppm nitric oxide gas group. Methemoglobin levels >7% were attained only in patients receiving 80 ppm, where they comprised 35% of the group. The average time to reach peak methemoglobin was 10 ± 9 (SD) hours (median, 8 hours) in these 13 patients, but one patient did not exceed 7% until 40 hours.

Elimination

Nitrate has been identified as the predominant nitric oxide metabolite excreted in the urine, accounting for >70% of the nitric oxide dose inhaled. Nitrate is cleared from the plasma by the kidney at rates approaching the rate of glomerular filtration.
Triple-negative breast cancer (TNBC) is characterized by earlier recurrence and shorter survival compared with other types of breast cancer. Moreover, approximately 15 to 25% of all TNBC patients harbor germline BRCA (gBRCA) 1/2 mutations, which confer a more aggressive phenotype. However, TNBC seems to be particularly sensitive to chemotherapy, the so-called 'triple negative paradox'. Therefore, Neoadjuvant chemotherapy (NACT) is currently considered the preferred approach for early-stage TNBC. BRCA status has also been studied as a predictive biomarker of response to platinum compounds. Although several randomized trials investigated the addition of carboplatin to standard NACT in early-stage TNBC, the role of BRCA status remains unclear. In this retrospective analysis, data from 136 consecutive patients with Stage I-III TNBC who received standard NACT, with or without the addition of carboplatin, will be evaluated in order to define clinical features and outcomes in BRCA 1/2 mutation carriers and non-carrier controls.
<P>PROBLEM TO BE SOLVED: To provide a soap containing active components extracted from indigo which has been widely utilized from a long time ago as a dye for underwear and is expected to have functions such as antibacterial action and antiinflammatory action as one of soaps containing various ingredients and meeting the recent health boom demanding natural toilet soap.  <P>SOLUTION: Precipitated indigo produced by fermenting and eluting indigo leaf is dissolved together with sodium hydroxide into an aqueous solution obtained by extracting water-soluble components of the seed of Japanese indigo plant. Oil-soluble components of indigo leaf are decocted with a vegetable oil such as olive oil and the vegetable oil containing the oil-soluble components of indigo is mixed with the aqueous solution under stirring to saponify the components. The product is put into a mold and solidified by leaving at rest to obtain the soap. A soap having desired composition can be produced by using the extracted component singly or in combination and varying the concentration.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
### Teratogenic Effects: Pregnancy Category D

See WARNINGS section. Floxuridine has been shown to be teratogenic in the chick embryo, mouse (at doses of 2.5 to 100 mg/kg) and rat (at doses of 75 to 150 mg/kg). Malformations included cleft palates, skeletal defects and deformed appendages, paws and tails. The dosages which were teratogenic in animals were 4.2 to 125 times the recommended human therapeutic dose.

There are no adequate and well-controlled studies with floxuridine in pregnant women. While there is no evidence of teratogenicity in humans due to floxuridine, it should be kept in mind that other drugs which inhibit DNA synthesis (e.g., methotrexate and aminopterin) have been reported to be teratogenic in humans. Floxuridine should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

### Nonteratogenic Effects

Floxuridine has not been studied in animals for its effects on peri- and postnatal development. However, compounds which inhibit DNA, RNA and protein synthesis might be expected to have adverse effects on peri- and postnatal development.
Larger patient cohorts are needed to support the clinical trials coming in the next 3-5 years. Despite widespread invitations to the Alpha-1 community from the Alpha-1 Foundation Research Registry, it is estimated that the Alpha-1 Foundation Research Registry now contains \<40% of the identified PiZZ individuals in the US.
OBJECTIVE: Intraoperative hypotension remains a serious adverse event of photodynamic diagnosis-assisted transurethral resection of bladder tumor with oral administration of 5-aminolevulinic acid. We conducted a re-analysis of perioperative hypotension in photodynamic diagnosis-assisted transurethral resection of the bladder tumor with oral 5-aminolevulinic acid to ascertain its safety.
METHODS: A total of 407 cases who underwent transurethral resection of bladder tumors in our institution were reviewed (274 cases for the PDD group with photodynamic diagnosis and 133 for the white light (WL) group without). A classification of hypotension severity was devised to identify risk factors for clinically troublesome hypotension. The distribution of hypotension severity in each of the PDD and WL groups was compared. Additionally, the patient background and perioperative data by hypotension severity were compared only in the PDD group.
RESULTS: More patients with moderate and severe hypotension were noted in the PDD group. The renal function was lower with increasing hypotension severity in the PDD group. More patients on general anesthesia were included in the mild and moderate hypotension group, whereas more patients on spinal anesthesia were included in the severe hypotension group. Furthermore, the frequency of side effects other than hypotension tended to increase with hypotension severity.
CONCLUSIONS: Renal function impairment and the other adverse effects of 5-aminolevulinic acid may be risk factors for severe hypotension. Mild or moderate hypotension may be caused by general anesthesia and severe hypotension may be caused by spinal anesthesia. To elucidate specific risk factors, further case-control studies are warranted.
FIELD: biotechnology. SUBSTANCE: to obtain all-virion vaccine against human cytomegalovirus an AD-169 strain is used. Virus is grown upon a monolayer of diploma cells prelocated into growth medium. Virus cellular releasing is performed at a single cycle of monolayer freezing and thawing. Vaccine purification against detritus is performed by a low-rate centrifuging. As a cellular line one should use diploid cells of human fibroblasts (M-22 line) or renal cellular line of green marmosets VERO-B. Cytomegalovirus is inactivated by formalin at 1:2000 concentration at 37C for 3 d, and at 4 ° +1 °  C for 10 d, or by cobalt-60 for 2 h at 19-21 C. Immunogenicity is evaluated by B-cellular index of lymphocytic activity (synthesis of virus-neutralizing antibodies at vaccinating experimental animals). Vaccine is used as a suppository containing, except cytomegalovirus, 20.0 ml (10 6  tissue cytopathogenic CMV doses) polyoxydonium 0.02 g, hyaluronic acid 1.0 g. Suppositorial base is supplemented with confectionary fat, paraffin and emulsifiers - up to 100.0 g weight. EFFECT: higher efficiency in obtaining virus-specific immunity in experimental animals. 3 cl
Cystic Fibrosis (CF) is an autosomal recessive genetic disease, caused by mutations of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) that impairs ion transport at epithelial surfaces. This results in the accumulation of dehydrated secretions in the airways and chronic infection and inflammation in the lungs, leading to significant morbidity and mortality. The investigators understanding of CF pathogenesis has increased substantially and many new targeted therapies are being developed to treat this disease, however, the measurements of clinical efficacy used to evaluate these therapies require long trials to demonstrate an effect. New translational techniques are needed to assess changes in the most basic aspects of the disease and allow for the rapid screening of disease-altering therapies. The investigators have recently developed a novel aerosol-based imaging technique to measure liquid absorption in the airways - a central pathophysiological process related to CFTR dysfunction. The investigators propose that airway liquid hyper-absorption is a key link between cellular defects in ion and fluid transport and progressive airway dysfunction in CF. Thus The investigators technique may provide a measure of disease severity and rapid indication of therapeutic correction in advance of currently available outcome measures.
The invention discloses a capsule deficiency type Streptococcus equi subsp. zooepidemicus attenuated vaccine strain and a preparation method thereof, belonging to the technical field of animal vaccine preparation. The capsule deficiency type Streptococcus equi subsp. zooepidemicus attenuated vaccine strain is named Streptococcus equi subsp. zooepidemicus C55138 delta hasB, and was preserved in  CCTCC (China Center for Type Culture Collection) on May 14, 2012 with the preservation number of CCTCC NO:M 2012164. The strain is constructed by hasB gene inactivation caused by allele replacing, is attenuated in toxicity, and can be used for preparing vaccine for Streptococcus equi disease. The vaccine production process is simple, the vaccine strain can be cultured on a large scale, the cost is low and the period is short; the vaccine presents cellular immunity and humoral immunity; and the vaccine is low in dosage, high in safety, low in toxicity and convenient for use, and can be popularized and used all over the world.
Intracranial aneurysm (IA) is now a common term closely associated with subarachnoid hemorrhage. IA is the bulging of a blood vessel caused by a weakening of its wall. This bulge can rupture and, in most cases, cause internal bleeding. In most cases, internal bleeding leads to death or other fatal consequences. Therefore, the development of an automated system for detecting IA is needed to help physicians make more accurate diagnoses. For this reason, we have focused on this problem. In this paper, we propose a 2D Convolutional Neural Network (CNN) based on a network commonly used for data classification in medicine. In addition to our proposed network, we also tested ResNet 50, ResNet 101 and ResNet 152 on a publicly available dataset. In this case, ResNet 152 achieved better results than our proposed network, but our network was significantly smaller and the classifications took significantly less time. Our proposed network achieved an overall accuracy of 98%. This result was achieved on a dataset consisting of 611 images. In addition to the mentioned networks, we also experimented with the VGG network, but it was not suitable for this type of data and achieved only 20%. We compare the results in this work with neural networks that have been verified by the scientific community, and we believe that the results obtained by us can help in the creation of an automated system for the detection of IA.